CTLA4 and cancer: The development of immunotherapies that target T cell cosignaling is now a major focus within immunotherapy research (62, 63), and the successful use of PD-1 and CTLA-4-specific monoclonal antibodies in cancer treatments has provided clear evidence of its efficacy (22, 64).